A comprehensive analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder

Objective: To examine the role of autosomal dominant (AD) and recessive (AR) Parkinsonism genes in the risk of isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD). Methods: Ten genes implicated in AD and AR Parkinsonism were fully sequenced using targeted next-generation sequencing in 1,039 iRBD patients and 1,852 controls of European ancestry. These include the AR genes PRKN, DJ-1 (PARK7), PINK1 , VPS13C, ATP13A2, FBXO7 and PLA2G6, and the AD genes LRRK2, GCH1 and VPS35 . To examine the role of rare heterozygous variants in these genes, burden test and SKAT-O analyses were performed. The contribution of homozygous and compound heterozygous variants was further examined in the AR genes. Copy number variants (CNVs) in PRKN were tested in a subset of samples (n=374) using multiplex ligation-dependent probe amplification followed by analysis of all samples using ExomeDepth. Results: We found no association between rare heterozygous variants in the tested genes and risk for iRBD. Several homozygous and compound heterozygous carriers were identified with variants of unknown significance, yet there was no overrepresentation in iRBD patients versus controls. Conclusion: Our results do not support a major role for variants in PRKN, PARK7, PINK1 , VPS13C, ATP13A2, FBXO7, PLA2G6, LRRK2, GCH1 and VPS35 in the risk of iRBD.


Introduction
Isolated rapid eye movement (REM)-sleep behavior disorder (iRBD) is a prodromal neurodegenerative disease. More than 80% of iRBD patients diagnosed with videopolysomnography (vPSG) will eventually convert to an overt α -synucleinopathy. 1 These include mostly Parkinson's disease (PD) and dementia with Lewy bodies (DLB), and a small minority will convert to multiple system atrophy (MSA). 2 While not much is known about the genetic background of DLB and MSA, accumulating data from the last two decades have unraveled the role of common and rare genetic variants in PD. Currently, 90 independent risk factors of PD in 78 genetic loci are known, discovered through genome-wide association studies (GWAS). 3 Other, less common genetic variants, have been implicated in familial forms of PD, including autosomal dominant (AD) inherited variants in genes such as SNCA, LRRK2, GCH1 and VPS35, 4-6 and autosomal recessive (AR) inherited variants in PRKN, PINK1 and PARK7. 7 Bi-allelic mutations in other genes, including ATP13A2, VPS13C, FBXO7 and PLA2G6 may cause AR atypical syndromes with Parkinsonism,4,8 in some of which α -synucleinopathy has also been reported. [9][10][11] The genetic background of iRBD has only been studied in recent years, with studies showing that there is no full genetic overlap between the genetic background of iRBD and that of PD or DLB. For example, GBA mutations are associated with risk of iRBD, PD and DLB, 2,12 but pathogenic LRRK2 mutations seem to be involved only in PD and not in iRBD and DLB. 8,13,14 MAPT and APOE variants are important risk factors of PD and DLB, respectively, 15,16 but both genes are not associated with iRBD. 15,17 In the SNCA locus, there are independent risk variants of PD, DLB and iRBD; specific 3' variants are associated with PD, and other, independent variants at the 5' of SNCA are associated with iRBD and DLB. 18 Within the TMEM175 locus, there are . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020March 20, . . https://doi.org/10.1101March 20, /2020 doi: medRxiv preprint M u f t i two independent risk factors of PD, but only one of them, the coding polymorphism p.M393T, has also been associated with iRBD. 19 Thus far, the role of most of the familial PD genes or genes involved in rare forms of atypical parkinsonism has not been studied in iRBD. Here, since GBA and SNCA have been studied previously, 2,18 we aimed to thoroughly examine the roles of PRKN, PINK1, PARK7 (DJ-1), VPS13C, ATP13A2, FBXO7, PLA2G6, LRRK2, GCH1 and VPS35 in iRBD.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Population
A total of 1,039 unrelated iRBD patients and 1,852 unrelated controls were included in this study, all of European ancestry (confirmed by principal component analysis of GWAS data).
Approximately 81% of the patients were male, the mean reported age at onset (AAO) was 60.1 ± 10.5 years and the average age at diagnosis was 65.3 ± 8.7 years. Data on sex and age were available for 1,032 and 1,004 patients, respectively. Among the controls, about 51% were male, and the mean age at sampling was 52.3 ± 14.3 years, age was not available for nine controls.
RBD diagnosis was done with video polysomnography according to the ICSD-2/3 criteria (International Classification of Sleep Disorders, version 2 or 3). 20

Standard protocol approvals, registrations, and patient consents
All patients signed an informed consent form before entering the study, and the study protocol was approved by the institutional review boards.

Genetic analysis
The coding sequences and 5' and 3' untranslated regions (UTRs) of PRKN, PINK1, DJ-1, VPS13C, ATP13A2, FBXO7, PLA2G6, LRRK2, GCH1 and VPS35 were captured using molecular inversion probes (MIPs) designed as previously described, 21 and the full protocol is available upon request. Details of the MIPs used in the current study are listed in Supplementary is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) annotation with ANNOVAR. 24 The Frequency of each variant was extracted from the Genome Aggregation Database (GnomAD). 25 We used ClinVar and specific searches on PubMed to examine whether variants that were found in these genes are known or suspected to be pathogenic in PD or atypical parkinsonism.

Quality control
To perform quality control (QC), we used the PLINK software. We excluded variants with:

Availability of data and materials
Data used for the analysis is available in the supplementary tables. Anonymized raw data can be shared upon request from any qualified investigator.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Quality of coverage
The average coverage of the 10 genes analyzed in this study was >144X for all genes, and the coverage of 8 of the genes was >900X. The per-gene coverage for all 10 genes, although not perfect, is better than the coverage of these specific genes in gnomAD. Supplementary Table 2 details the average coverage and the percentage of nucleotides covered at 20X and 50X for each gene. There were no differences in the coverage across the samples (patients and controls).

Rare homozygous and compound heterozygous variants are not enriched in iRBD patients
To examine whether homozygous or compound heterozygous variants in our genes of interest may cause iRBD, we compared the carrier frequencies of very rare (MAF <0.001) bi-allelic variants between iRBD patients and controls. Three carriers (one patient and two controls) were identified with homozygous variants across all genes. All three carried homozygous non-coding variants that are not likely to cause a disease: one male patient with AAO of 76 years who carried the PINK1 variant rs181532922, c.*717T>C at the 3' UTR of the gene, one female control recruited at age 72 who carried the DJ-1 rs7534132, an intronic variant, and one control recruited at the age of 26 who carried the LRRK2 rs72546315 synonymous (p.H275H) variant.
For the analysis of compound heterozygous carriers, since phasing could not be performed, we considered carriers of two rare variants as compound heterozygous carriers, with two exceptions: 1) when variants were physically close and we could determine their phase based on the sequence reads and 2) if the same combination of very rare variants appeared more than once, we assumed that the variants are likely on the same allele. We found a total of 9 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. .
in PRKN, and two additional controls with the PRKN p.T240M pathogenic variant. One patient and one control with the pathogenic variant p.R299C in FBXO7 were also found.

Analysis of copy number variants in PRKN
We further examined the association between deletions and duplications in PRKN and risk for iRBD. Using ExomeDepth, 7 patients (0.7 %) and 17 controls ( . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. .

Discussion
The present study provides the first large-scale, full sequencing analysis to examine the possible role of the dominant and recessive parkinsonism genes PRKN, PARK7, PINK1, VPS13C, ATP13A2, FBXO7, PLA2G6, LRRK2, GCH1 and VPS35 in iRBD. We did not find evidence for association of any of these genes with iRBD. In the recessive genes, there was no overrepresentation of carriers of homozygous or compound heterozygous variants in iRBD patients, and no single patient with bi-allelic pathogenic variants. In the dominant genes, we did not find any known pathogenic variants in these genes, and SKAT-O and burden analyses did not identify burden of rare heterozygous variants in any of these 10 genes.
Whether heterozygous carriage of mutations in recessive PD or atypical parkinsonism related genes is a risk factor for PD is still controversial. 29 PRKN-associated PD is characterized by pure nigral degeneration without α -synuclein accumulation, 30 and reports on synucleinopathy and Lewy bodies in PINK1-associated PD are inconclusive, as some studies identified Lewy bodies while others did not. 31,32 Since iRBD is a prodromal synucleinopathy, it is not surprising that we did not identify bi-allelic mutations or burden of heterozygous variants in any of these genes. Of note, 380 (36.5%) of the iRBD cohort had a self-reported AAO <50 years. In the case of iRBD, reported AAO may be especially unreliable, as patients may have had RBD symptoms long before they were noticed by themselves or their bed partners. Therefore, the true percentage of iRBD patients with AAO <50 is likely higher, yet none of the known genes involved in early onset PD seems to be involved in early onset iRBD.
Recently, we have shown that the SNCA locus is important in RBD, yet with different and distinct variants that are associated with risk of PD. 18 In the same study, SNCA was fully sequenced and no known PD-causing variants were found in iRBD patients. We and others have . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. . Our study has some limitations. While being the largest genetic study of iRBD to date, it may still be underpowered to detect rare variants in familial PD-related genes. Therefore, our study does not completely rule out the possibility that variants in these genes may lead to iRBD in very rare cases. Another potential limitation of the study design is the earlier age and the different sex distribution in the control population, and the fact that they have not been tested for iRBD. However, since iRBD is not common, found in about 1% of the population, 1 age would have a minimal or no effect on the results. The differences in sex ratios are less likely to have an effect, since in AD and AR Mendelian diseases, the risk is typically similar for men and women.
To conclude, the lack of association between different PD and Parkinsonism genes may suggest that either iRBD is an entity more affected by environmental factors, or that there are other, yet undetected genes that may be involved in iRBD. To examine these possibilities, larger studies that include carefully collected epidemiological data and more extensive genetic data such as whole-exome or whole-genome sequencing will be required. Our study also suggests that screening for variants in the tested genes will have a very low yield.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. .  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted March 20, 2020March 20, . . https://doi.org/10.1101March 20, /2020 doi: medRxiv preprint M u f t i  revised the manuscript for intellectual content . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 20, 2020. revised the manuscript for intellectual content . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 20, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 20, 2020. . https://doi.org/10.1101/2020